Commonwealth Bank of Australia’s Alnylam Pharmaceuticals ALNY Stock Holding History

Commonwealth Bank of Australia’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-43	Closed	-$3K	–	48
2019 Q2	$3K	Hold	43	–	–	﹤0.01%	1128
2019 Q1	$4K	Hold	43	–	–	﹤0.01%	1116
2018 Q4	$3K	Buy	43 +23	+115%	+$1.77K	﹤0.01%	1125
2018 Q3	$1K	Hold	20	–	–	﹤0.01%	1152
2018 Q2	$1K	Buy	+20	New	+$1.98K	﹤0.01%	833
2017 Q1	–	Sell	-600	Closed	-$22K	–	885
2016 Q4	$22K	Buy	600 +300	+100%	+$12.6K	﹤0.01%	817
2016 Q3	$20K	Hold	300	–	–	﹤0.01%	821
2016 Q2	$17K	Hold	300	–	–	﹤0.01%	787
2016 Q1	$19K	Buy	300 +200	+200%	+$13.3K	﹤0.01%	798
2015 Q4	$9K	Buy	+100	New	+$9.27K	﹤0.01%	830
2014 Q2	–	Sell	-6,077	Closed	-$408K	–	790
2014 Q1	$408K	Buy	6,077 +177	+3%	+$13.7K	﹤0.01%	1086
2013 Q4	$379K	Buy	+5,900	New	+$352K	﹤0.01%	1087

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Commonwealth Bank of Australia's ALNY Position: Q3 2019 in Review

Commonwealth Bank of Australia sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2019, closing a stake of 43 shares — an estimated $3K sold.

Commonwealth Bank of Australia first reported a position in ALNY in Q4 2013 and held it in 12 quarters. The position peaked at $408K in Q1 2014. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Commonwealth Bank of Australia reported no remaining Alnylam Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Commonwealth Bank of Australia sold 43 Alnylam Pharmaceuticals shares in Q3 2019, an estimated $3K.
Commonwealth Bank of Australia first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 12 quarters.
Commonwealth Bank of Australia's Alnylam Pharmaceuticals position peaked at $408K in Q1 2014.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Commonwealth Bank of Australia's 13F filing for Q3 2019.